Horse Owners

When riding your horse doesn’t feel right, you know it. See how arthritis can affect every ride together.

WHY ADEQUAN I.M.?

Veterinarians

Equine arthritis can affect horses at any stage. Diagnosing and treating it early can help improve patient outcomes.

SEE WHY IT MATTERS

Committed to Horses

Proud sponsor of passion, performance, and people.

SEE OUR PARTNERS

Mobility makes
all the difference

Adequan® i.m. (polysulfated glycosaminoglycan) is unlike any other equine joint product. For over 30 years, it’s been used by veterinarians to help horses of every discipline and level enjoy greater mobility over their lifetimes.1,3,4

Adequan i.m. has been proven to work in multiple ways to maintain joint function:1,2

REDUCE

inflammation

RESTORE

synovial joint lubrication

REPAIR

joint cartilage

REVERSE

the disease process

INDICATIONS
Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.

Follow recommended dosing for the best results

When administered according to the recommended dosing schedule, Adequan i.m. not only reaches joints quickly, it also helps to protect and renew joint mobility.1,2 It has a demonstrated safety profile with no known injection site reactions or blood clotting issues.

Advancing joint care for dogs & horses

For more than 30 years, veterinarians have relied on the American Regent Animal Health family of products to provide solutions that help support joint health in their patients. Our mission is to champion the long-term well-being and mobility of animals, from top athletes to family companions.

  1. Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57.
  2. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
  3. Adequan® i.m. (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.
  4. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.